Sanofi opens new Alzheimer's Phase 2 for SAR448851 alongside gastric cancer trial

Sanofi's newest addition this week is a Phase 2 trial in early Alzheimer's disease, alongside continued progress on a gastric cancer study and older items in leukemia, hemophilia, and Pompe disease.

• SAR448851, an oral once-daily drug for early Alzheimer's disease, is recruiting in a new Phase 2 study. This is a randomized, placebo-controlled Phase 2 study to evaluate the efficacy and safety of SAR448851 in early Alzheimer's disease participants, measuring efficacy and safety with once daily oral SAR448851 compared to placebo in participants with mild cognitive impairment due to AD or mild AD dementia and with evidence of cerebral amyloid pathology.¹ Up to 160 participants will be included in this study.¹
• SAR445877, a Phase 2 study in Chinese patients with advanced gastric or gastroesophageal junction cancer, continues recruiting. The trial will assess SAR445877 as a monotherapy in approximately 30 participants with advanced unresectable or metastatic GC or Siewert Type 2 and 3 GEJ, and for whom receiving the standard of care is not in his or her best interest, or where no SOC is established.²
• SAR443579, an IV-infused drug tested in relapsed or refractory AML, B-ALL, HR-MDS, or BPDCN, had its terminated Phase 1/2 study post final results. The study was terminated early based on a strategic sponsor decision not driven by any safety concerns.³ Results were first posted 2026-07-06 (actual), with enrollment of 101 participants (actual).³
• A University of Texas Southwestern Medical Center study comparing factor VIII replacement therapies in children with hemophilia A, with Sanofi as collaborator, is not yet recruiting. The study aims to compare how children with moderate or severe hemophilia A respond when treated with prophylactic extended half-life factor VIII based replacement therapy (such as Altuviiio) versus non-FVIII based replacement therapy (such as Hemlibra) as part of their hemophilia treatment to prevent spontaneous joint bleeds.⁴
• An observational study from Hospitales Universitarios Virgen del Rocío in Spain, with Sanofi as collaborator, is completed. It enrolled participants with genetically confirmed late-onset Pompe disease, collecting clinical, laboratory, genetic, and vascular imaging data to determine the prevalence and characteristics of cerebrovascular and aortic vascular abnormalities.⁵